OmniAb, Inc. (NASDAQ:OABI – Get Rating) Director Jennifer R. Cochran acquired 22,250 shares of OmniAb stock in a transaction on Tuesday, December 6th. The shares were bought at an average cost of $3.75 per share, with a total value of $83,437.50. Following the completion of the purchase, the director now owns 77,476 shares in the company, valued at $290,535. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
OmniAb Price Performance
Shares of OABI stock opened at $3.60 on Friday. OmniAb, Inc. has a 12-month low of $1.91 and a 12-month high of $10.50.
Analyst Ratings Changes
Several analysts have commented on the company. SVB Leerink assumed coverage on OmniAb in a research note on Tuesday, November 29th. They set an “outperform” rating and a $6.00 price objective for the company. Stifel Nicolaus assumed coverage on OmniAb in a research note on Monday, November 28th. They set a “buy” rating and a $12.00 price objective for the company.
OmniAb Company Profile
OmniAb, Inc, a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
- Get a free copy of the StockNews.com research report on OmniAb (OABI)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify’s Downtrend?
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.